Fabry disease
Fabry disease is a rare genetic disorder that affects the body's ability to break down a type of fat called globotriaosylceramide (GL-3). This leads to the accumulation of GL-3 in cells, particularly in the kidneys, heart, and nervous system.
The symptoms of Fabry disease vary depending on the severity of the condition and the age of onset, but they can include:
• Pain in the hands and feet (acroparesthesia)
• Skin rashes
• Cloudy vision
• Hearing loss
• Tinnitus
• Difficulty swallowing
• Heart problems
• Kidney damage
• Stroke
• Cognitive
impairment Fabry disease is caused by a defect in the GLA gene, which provides instructions for making the enzyme alpha-galactosidase A. This enzyme is responsible for breaking down GL-3. When the GLA gene is defective, the enzyme is not produced or does not function properly, leading to the accumulation of GL-3 in cells. The GLA gene is found on the X chromosome, which demonstrates that Fabry disease is inherited on an X-linked way.
Since females have two X chromosomes and males have one X and one Y chromosome, the disease affects males more severely than females. Males with Fabry disease have a 50% chance of passing the disease on to their sons, and females have a 50% chance of passing it on to each of their children. Diagnosis of Fabry disease is based on a combination of clinical signs and symptoms, family history, and laboratory tests. Genetic testing can confirm the diagnosis by identifying a mutation in the GLA gene.
Treatment
Treatment for Fabry disease is aimed at reducing the accumulation of GL-3 in cells and preventing or slowing down the progression of the disease. Enzyme replacement therapy (ERT) is the most common treatment for Fabry disease. ERT replaces the missing or defective enzyme with a functional version of the enzyme, which helps break down GL-3. This treatment is usually administered by injection every two weeks.
Gene therapy
Gene therapy is also in development for Fabry disease. This is a relatively new approach that aims to deliver a functional copy of the GLA gene to cells, thereby restoring the production of alpha-galactosidase A. Prognosis of Fabry disease depends on the severity of the condition and the age of onset, but it can be fatal if left untreated. However, the prognosis can be enhanced with early detection and appropriate care. Regular monitoring and follow-up are necessary to detect and manage any complications that may arise.
In summary
Fabry disease is a rare genetic disorder that affects the body's ability to break down a type of fat called globotriaosylceramide (GL-3). It is caused by a defect in the GLA gene, and symptoms can include pain in the hands and feet, skin rashes, cloudy vision, hearing loss, and heart and kidney problems. Diagnosis is based on a combination of clinical signs and symptoms, family history, and laboratory tests. Treatment options include enzyme replacement therapy and gene therapy, which can help slow down the progression of the disease and improve the prognosis.
